Fresenius Medical Care AG & Co. KGaA (FME) Price & Analysis

Compare

14 Followers

FME Stock Chart & Stats

Day’s Range― - ―

52-Week Range€35.00 - €54.02

Previous CloseN/A

Volume12.09K

Average Volume (3M)587.63K

Market Cap

€12.32B

Enterprise Value€24.64B

Total Cash (Recent Filing)€2.19B

Total Debt (Recent Filing)€11.02B

Price to Earnings (P/E)18.8

Beta0.79

Next Earnings

Nov 04, 2025

EPS Estimate

Last Dividend Ex-Date

May 23, 2025

Dividend Yield3.36%

Share Statistics

EPS (TTM)0.91

Shares Outstanding293,413,450

10 Day Avg. Volume642,533

30 Day Avg. Volume587,626

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€48.86

Price Target Upside14.03% Upside

Rating ConsensusHold

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Clinical EfficiencyThe CONVINCE trial showed a 22% reduction in mortality, highlighting the clinical efficiency and patient benefit of the 5008x rollout.

Cost ManagementFresenius continues to execute on FME25 savings, achieving strong traction with €128mn in the first half against an annual target of €180mn.

Strategic InitiativesThe first tranche of the buyback is planned to begin, and the HV HDF rollout is positioned to begin soon, which are positive updates.

Bears Say

Foreign Exchange ImpactEstimates for FY25/FY26 are being lowered by 1-3% due to expected foreign exchange headwinds of 3-4% in FY25.

Investor ConcernsThe lack of guideline for mid-term topline growth is the largest area of investor concern, especially with structural challenges.

Market ReactionExpectations were running high into the CMD, and the updated targets were largely factored into the share price, resulting in a 'sell the news' reaction with shares down 5%.

Fresenius Medical Care AG & Co. KGaA News

Fresenius Medical downgraded to Sell from Neutral at UBS

UBS downgraded Fresenius Medical (FMS) to Sell from Neutral with a price target of EUR 38, down from...

9d ago

FMS

Fresenius Medical price target raised to EUR 46 from EUR 43 at Morgan Stanley

Morgan Stanley analyst Robert Davies raised the firm’s price target on Fresenius Medical (FMS) to EUR 46 from...

29d ago

FMS

Fresenius Medical announces first tranche of share buyback program

Fresenius Medical (FMS) Care announced the launch of the first tranche of its initial EUR 1B share buyback,...

1M ago

FMS

Fresenius Medical price target lowered to EUR 48 from EUR 50 at Deutsche Bank

Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Fresenius Medical (FMS) to EUR 48 from...

1M ago

FMS

Hold Rating Maintained for Fresenius Medical Care Amidst Flat US Growth and Downward Financial Adjustments

In a report released today, Julien Ouaddour from Bank of America Securities reiterated a Hold rating on Fresenius...

1M ago

FMS

Fresenius Medical reports Q2 adjusted EPS EUR0.91 vs. EUR0.72 last year

Reports Q2 revenue EUR4.79B vs. EUR4.77B last year. “In Q2 2025, we further improved our operational performance as...

1M ago

FMS

Fresenius Medical still sees 2025 revenue growth in low-single digits

2024 revenue was EUR19.34M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

1M ago

FMS

Hold Rating for Fresenius Medical Care AG & Co. KGaA Amid Stable U.S. Growth and Structural Challenges

In a report released today, Julien Ouaddour from Bank of America Securities reiterated a Hold rating on Fresenius...

2M ago

FMS

Fresenius Medical price target raised to EUR 50 from EUR 45 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Fresenius Medical (FMS) to EUR 50 from EUR 45 and...

2M ago

FMS

Fresenius Medical extends HighVolumeHDF dialysis in Mexico

Fresenius Medical (FMS) will extend High-Volume Hemodiafiltration access for patients in seven out of 10 centers in Mexico,...

2M ago

FMS

Fresenius Medical Care removed from European Conviction List at Goldman Sachs

Goldman Sachs analysts removed Fresenius Medical (FMS) Care from the firm’s European Conviction List as part of its...

2M ago

FMS

Fresenius Medical price target raised to EUR 60 from EUR 55 at Berenberg

Berenberg raised the firm’s price target on Fresenius Medical (FMS) to EUR 60 from EUR 55 and keeps...

3M ago

FMS

Fresenius Medical Care: Hold Rating Amid Ambitious Targets and Execution Risks

Bank of America Securities analyst Julien Ouaddour reiterated a Hold rating on Fresenius Medical Care AG & Co....

3M ago

FMS

Fresenius Medical Care: Balanced Outlook with Hold Rating Amid Mixed Growth Signals

In a report released today, Marianne Bulot from Bank of America Securities reiterated a Hold rating on Fresenius...

4M ago

FMS

FME FAQ

What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?

Fresenius Medical Care AG & Co. KGaA lowest stock price was €35.00 and its highest was €54.02 in the past 12 months.

What is Fresenius Medical Care AG & Co. KGaA’s market cap?

Fresenius Medical Care AG & Co. KGaA’s market cap is €12.32B.

When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?

Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Nov 04, 2025 which is in 54 days.

How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?

Fresenius Medical Care AG & Co. KGaA released its earnings results on Aug 05, 2025. The company reported €0.91 earnings per share for the quarter, beating the consensus estimate of €0.874 by €0.036.

Is Fresenius Medical Care AG & Co. KGaA overvalued?

According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fresenius Medical Care AG & Co. KGaA pay dividends?

Fresenius Medical Care AG & Co. KGaA pays a Annually dividend of €1.44 which represents an annual dividend yield of 3.36%. See more information on Fresenius Medical Care AG & Co. KGaA dividends here

What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?

Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 1.

How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?

Fresenius Medical Care AG & Co. KGaA has 293,413,450 shares outstanding.

What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?

Fresenius Medical Care AG & Co. KGaA reported an EPS of €0.91 in its last earnings report, beating expectations of €0.874. Following the earnings report the stock price went down -1.755%.

Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?

Currently, no hedge funds are holding shares in DE:FME

Fresenius Medical Care AG & Co. KGaA Stock Smart Score

Underperform

Fundamentals

Return on Equity

4.83%

Trailing 12-Months

Asset Growth

-7.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA (FME) is a global healthcare company based in Germany, specializing in products and services for individuals with renal diseases. With a strong focus on dialysis, the company operates in two primary segments: the production of dialysis products, including machines and consumables, and the provision of dialysis treatment services through its extensive network of outpatient clinics and in-center facilities. Fresenius Medical Care is a leader in the renal care market, aiming to improve the quality of life for patients with chronic kidney failure.

Fresenius Medical Care AG & Co. KGaA (FME) Earnings & Revenues

Historic Earnings Reports

FME Stock 12 Month Forecast

Average Price Target

€48.86

▲(14.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"€32","61":"€61","39.25":"€39.3","46.5":"€46.5","53.75":"€53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€48.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,39.25,46.5,53.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.04,45.26769230769231,46.495384615384616,47.723076923076924,48.95076923076923,50.17846153846154,51.40615384615385,52.63384615384615,53.86153846153846,55.08923076923077,56.316923076923075,57.54461538461538,58.77230769230769,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.04,44.41076923076923,44.78153846153846,45.152307692307694,45.52307692307692,45.893846153846155,46.26461538461538,46.635384615384616,47.00615384615384,47.37692307692308,47.747692307692304,48.11846153846154,48.48923076923077,{"y":48.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.04,43.575384615384614,43.11076923076923,42.646153846153844,42.18153846153846,41.716923076923074,41.252307692307696,40.78769230769231,40.323076923076925,39.85846153846154,39.393846153846155,38.92923076923077,38.464615384615385,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.708,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.317,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":35.342,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":41.907,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":42.948,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46.721,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.126,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":44.621,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":43.288,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":50.4,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":48.8,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":43.28,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >